clinical trial · NCT07545460
A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
Sichuan Baili Pharmaceutical Co., Ltd.·phase3·not yet recruiting·n = 404
Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal CancerBL-M07D1Liposomal DoxorubicinPaclitaxelTopotecan
brief summary
This trial is a registrational Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-M07D1 in patients with HER2-expressing platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.
started
Apr 1, 2026
primary completion
Dec 1, 2028
completion
Dec 1, 2028
last updated
Apr 22, 2026
detailed description
In this trial, the treatment group will receive BL-M07D1, while the control group will receive physician's choice of chemotherapy (liposomal doxorubicin, paclitaxel, or topotecan).
official title
A Phase III Randomized Controlled Clinical Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol